Octreotide

What is Octreotide?

Octreotide is a synthetic octapeptide analogue of somatostatin with a much longer half-life (1.5 hours vs 2 minutes for native somatostatin). It is FDA-approved for acromegaly, carcinoid syndrome, and VIPomas. It suppresses growth hormone, insulin, glucagon, and various GI hormones.

What Octreotide Is Investigated For

Octreotide is an FDA-approved synthetic somatostatin analogue used for acromegaly, carcinoid syndrome, and VIPoma-related secretory diarrhea — three indications where it has been a core therapy since the late 1980s and carries decades of large-scale clinical evidence. The strongest evidence is for acromegaly (biochemical control of GH/IGF-1 excess) and for symptom control in neuroendocrine tumors, with dozens of randomized trials and meta-analyses supporting its labeled uses and multiple off-label uses (variceal hemorrhage adjunct, postoperative pancreatic fistula prevention, chemotherapy-related diarrhea). Emerging and off-label applications — tumor anti-proliferative effect in well-differentiated GEP-NETs, integration with PRRT/Lutathera regimens — have matured over the past decade into standard specialist practice. This is not a wellness peptide; it has a meaningful side-effect profile (gallstones, glycemic dysregulation, sinus bradycardia, cyclosporine interaction) and its use belongs in endocrinology, oncology, or gastroenterology hands. Off-label use for bodybuilding or HGH-side-effect management has no evidence base and carries real risk.

History & Discovery

Native somatostatin (somatotropin release-inhibiting factor) was identified in the early 1970s by Roger Guillemin's group at the Salk Institute as the hypothalamic peptide that suppresses pituitary growth-hormone release — work that contributed to Guillemin's 1977 Nobel Prize. Native somatostatin has a plasma half-life of roughly 2 minutes, which made therapeutic use impractical despite a clear pharmacological rationale for hormone-secreting tumors and acromegaly. Sandoz researchers in Basel — led by Wilfried Bauer — engineered octreotide in the late 1970s and early 1980s by truncating the parent 14-amino-acid peptide to a synthetic octapeptide with D-amino-acid substitutions that conferred protease resistance, extending plasma half-life roughly 30-fold while preserving SSTR2 and SSTR5 affinity. Octreotide (Sandostatin) received FDA approval in October 1988 for the management of carcinoid syndrome flushing and diarrhea, and for VIPoma-related diarrhea, with acromegaly approval following shortly. The 1990s saw broad uptake across endocrinology, oncology, and gastroenterology — for both labeled indications and a substantial off-label range including variceal hemorrhage, postoperative pancreatic fistula prevention, dumping syndrome, and chemotherapy-related diarrhea. Sandostatin LAR (long-acting release) — a microsphere-encapsulated depot enabling monthly intramuscular administration — was approved in the late 1990s and dramatically improved the practical management of acromegaly and metastatic neuroendocrine tumors. Octreotide laid the foundation for the broader somatostatin-analog class (lanreotide, pasireotide) and for theranostic applications using DOTATATE-radiolabeled analogs in neuroendocrine-tumor imaging and peptide receptor radionuclide therapy. After more than three decades on market, the molecule remains a core endocrine-oncology agent with extensive real-world safety and effectiveness data.

How It Works

Octreotide mimics somatostatin, the body's natural 'off switch' for many hormones. It tells the pituitary and gut to reduce hormone production, which is helpful when tumors are causing hormone overproduction.

Octreotide binds preferentially to somatostatin receptor subtypes SSTR2 and SSTR5, with moderate affinity for SSTR3. Receptor activation inhibits adenylyl cyclase, reducing cAMP and suppressing hormone secretion. It inhibits GH, TSH, insulin, glucagon, VIP, serotonin, and gastrin release. D-amino acid substitutions and a disulfide bridge confer protease resistance and extend half-life. The LAR (long-acting release) formulation uses microsphere technology for monthly dosing.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Octreotide:

• 01Long-term tumor-control benefit beyond symptom control — while PROMID and CLARINET established anti-proliferative effects in low-grade GEP-NETs, optimal sequencing with newer agents (Lutathera, everolimus, capecitabine/temozolomide) and durable survival benefit in modern combination regimens is still being clarified.
• 02Pasireotide vs. octreotide selection — the multi-receptor analog pasireotide has greater efficacy in some Cushing's disease and acromegaly populations but worse glycemic profile; predictors of which patients benefit from switching are incompletely defined.
• 03Optimal dosing and interval extension in well-controlled acromegaly — some patients tolerate extended LAR intervals (every 6–8 weeks) without loss of biochemical control; formal dose-extension protocols are not standardized.
• 04Oral octreotide (Mycapssa) real-world efficacy — approved in 2020 but real-world adherence, cost, and durability data relative to LAR injection are still maturing.
• 05Mechanism of post-octreotide gallstone formation — established epidemiologically but underlying biochemical mechanisms (cholesterol saturation, motility, bile-acid changes) are incompletely parsed.
• 06Use in non-FDA-approved indications (variceal bleeding adjunct, ERCP pancreatitis prophylaxis) — multiple meta-analyses, but heterogeneous results and modest effect sizes leave optimal dosing and patient-selection unresolved.

Forms & Administration

SC injection 2-3 times daily (100-600mcg/day) or monthly IM injection (Sandostatin LAR: 10-30mg). LAR formulation preferred for chronic use. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Octreotide is FDA-approved for acromegaly, carcinoid syndrome, and VIPoma; many other indications discussed here (variceal hemorrhage, postoperative pancreatic fistula, chemotherapy diarrhea) are off-label or supported by guideline use rather than FDA approval. It should be prescribed and monitored by an endocrinologist, oncologist, gastroenterologist, or other specialist familiar with somatostatin-analog therapy.

Timeline of Effects

Common Questions

Who Octreotide Is NOT For

Drug & Supplement Interactions

Octreotide produces several clinically meaningful drug interactions through both pharmacodynamic and pharmacokinetic mechanisms. Cyclosporine: octreotide significantly reduces cyclosporine absorption, potentially leading to subtherapeutic immunosuppression. Co-administration in transplant patients requires careful drug-level monitoring and dose adjustment. This interaction is the single most clinically important documented one for octreotide. Insulin and oral antihyperglycemic agents: octreotide alters glucose homeostasis through suppression of both insulin and glucagon, requiring monitoring and frequent dose adjustment of antidiabetic regimens, particularly during initiation and dose changes. Both hypoglycemia and hyperglycemia can occur depending on the underlying diabetic phenotype and concurrent therapy. Drugs metabolized by CYP3A4 with narrow therapeutic indices (warfarin, quinidine, terfenadine-class agents): octreotide may slow hepatic metabolism through reduced GH-driven CYP activity; close monitoring and dose adjustment is appropriate. Beta blockers, calcium channel blockers, and other agents that affect cardiac conduction: additive bradycardia risk warrants ECG monitoring. Octreotide can also affect fluid and electrolyte balance — combination with diuretics or other electrolyte-modulating agents requires monitoring. For patients on PRRT (Lutathera) for neuroendocrine tumors, the timing of long-acting octreotide relative to radionuclide administration must follow protocol-specific guidance to avoid receptor competition with the radiolabeled peptide; immediate-release octreotide is typically held in the days surrounding PRRT infusion.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions